What does it take to become a successful entrepreneur in the drug development space? The landscape of life science startups is no longer composed solely of companies with small molecule or biologic assets, but also includes machine learning technologies, platforms, and software tools to accelerate the R&D process.
The current era of bioinformatics presents opportunities and challenges to both Big Pharma and entrepreneurs alike. Johnson & Johnson Innovation, JLABS in cooperation with Data Collective (DCVC), has assembled a distinguished panel of experts to address how computational prowess can advance pharmaceutical development and shorten time to market as well as the breadth of obstacles faced by modern bioinformatics.
- What methods of partnering with Big Pharma have been most successful?
- Which models (SaaS, milestone payments, royalties, etc.) work for which situations?
- How are Software tools, bioinformatics, and data analyses increasing ROI for pharma R&D?
- What is 'machine learning' and how can it be used to accelerate drug discovery?
Our panel discussions are candid, interactive and informal. We hope you walk away with insights and knowledge that can help advance your work or overcome roadblocks. A networking session will take place after the panel.
3:00pm | Registration Opens and Networking
3:30pm | Introductions
3:35pm | Panel
5:00pm | Networking Reception
6:30pm | Program Close
Steve Quake | Co-Founder, Agenovenir read bio»
Matt Ocko | Co-Managing Partner & Co-Founder, DCVC read bio»
Max Hodak | CEO & Co-Founder, Transcriptic read bio»
Anthony Rowe | Director & Business Technology Leader for Immunology Therapeutic Area, Janssen Human Microbiome Institute, Janssen Immunoscience & Janssen Prevention Centre read bio»
[moderator] Pek Lum | CEO & Founder, CapellaBio read bio»
About Data Collective:
Data Collective is the first venture capital fund to invest exclusively in entrepreneurs building companies in the areas of Big Data and deep compute. Big Data companies capture, store, secure, transmit, transform, and analyze data for economic advantage, either with huge volumes (terabytes to exabytes), at tremendous speed (microseconds to seconds), or both.
According to a report by CB Insights, Data Collective was the most active investor in artificial intelligence startups in 2015.
Data Collective draws on a fund of just under $1 billion and invests early in a startup's development, focusing on Series Seed, Series A, and some select growth-stage companies. The firm has a unique model composed of 50+ Equity Partners with diverse experience ranging from academics at Stanford University to technical experts at Google and Twitter. These leaders help diligence deals and provide technical and industry vertical expertise. Additionally, a small set of Operating Partners with entrepreneurial experience also work with the portfolio at a deeper level to guide them toward success. With these resources at their disposal, Data Collective companies successfully raise subsequent rounds of capital from Silicon Valley firms ~95% of the time.
Healthcare, the life sciences, and the pharmaceutical industry are natural fits for Big Data technologies, which offer the potential for accelerated drug development, early diagnosis of disease, identification of gaps in care, and other advancements to optimize the patient experience and produce much more targeted, safe, and effective medicines. As such, healthcare has been a specific area of focus for the firm, with roughly 25-30% of the portfolio developing solutions in multiple areas of the healthcare ecosystem.
Data Collective has offices in San Francisco and Palo Alto, California. The firm's two founding and co-Managing Partners, Zachary Bogue and Matt Ocko, are deeply technical and are seasoned entrepreneurs, inventors, and venture capitalists.
$25 | General Public
$35 | Onsite
JLABS @ SSF
329 Oyster Point Blvd - 3rd Floor
South San Francisco, California
Steve Quake | Co-Founder, Agenovenir
Stephen Quake studied physics (BS 1991) and mathematics (MS 1991) at Stanford University, after which he earned a doctorate in theoretical physics from Oxford University (1994) as a Marshall Scholar. He then returned to Stanford University, where he spent two years as a postdoc in Steven Chu's group. Quake joined the faculty of the California Institute of Technology in 1996, where he rose through the ranks and was ultimately appointed the Thomas and Doris Everhart Professor of Applied Physics and Physics. At Caltech, Quake received "Career" and "First" awards from the National Science Foundation and National Institutes of Health and was named a Packard Fellow. These awards supported a research program that began with single molecule biophysics and soon expanded to include the inventions of single molecule sequencing and microfluidic large scale integration, and their applications to biology and human health. He moved back to Stanford University in 2005 to help launch a new department in Bioengineering, where he is now the Lee Otterson Professor and an Investigator of the Howard Hughes Medical Institute. Quake's contributions to the development of new biotechnology at the interface between physics and biology have been widely recognized. Honors include the Human Frontiers of Science Nakasone Prize, the MIT-Lemelson Prize, the Raymond and Beverly Sackler International Prize in Biophysics, the American Society for Microbiology Promega Biotechnology Research Award, the Royal Society of Chemistry Publishing Pioneer of Miniaturization Award, and the NIH Director's Pioneer Award. He is an elected fellow of the American Academy of Arts and Sciences, the National Academy of Inventors, the National Academy of Sciences, the National Academy of Engineering, the Institute of Medicine, the American Institute for Medical and Biological Engineering and of the American Physical Society.
Matt Ocko | Co-Managing Partner & Co-Founder, Data Collective Venture Capital (DCVC)
Matt Ocko, co-Managing Partner and co-founder of Data Collective (DCVC), has three decades of experience as a technology entrepreneur and VC, in the US and globally. In addition to large IPO outcomes, many of Matt's prior investments were acquired to become core capabilities of companies like Illumina, Cisco, Google, IBM, Amazon, and Akamai. He was also an early investor in Facebook (FB), Uber, AngelList, and Zynga (ZNGA). Matt's current investments in next generation bioinformatics, genomics, synthetic biology, and robotics and AI to accelerate discoveries in these fields include Transcriptic, Atomwise, Nervana, Zymergen, Vicarious, 3Scan, Diassess, D-Wave, Rigetti Quantum Computing, Scaled Inference, Ginkgo Bioworks, and several other large-scale but stealth companies. Matt holds a degree in Physics from Yale University, and he is an inventor on over 40 granted or in-process patents in areas ranging from computer systems virtualization to fraud detection. He has been active on a pro-bono basis in helping develop China's venture capital and technology regulatory framework for two decades.
Connect with Matt:
Max Hodak | CEO & Co-Founder, Transcriptic
Transcriptic is a robotic cloud laboratory for biology. We design, build, own and operate an automated molecular and cell biology infrastructure from our facility in Menlo Park, CA that scientists access remotely via a web browser over the internet. Our customers range from academic labs at Stanford, Harvard, UCSF, UCSD and more, to startups, to large biopharma. Our mission is to enable anyone to start and run a biotech company from a coffee shop with only a laptop, and enable individual scientists to achieve scale never before possible. Max studied biomedical engineering at Duke and worked in a lab studying multiunit electrophysiology in rhesus monkeys to build brain-machine interfaces. He started a company called MyFit to help match students and colleges (which resulted in a two year detour from college through Silicon Valley) that was sold to Naviance. At Transcriptic he is working on building better tools for scientists.
Connect with Max :
Anthony Rowe, Ph.D. | Director & Business Technology Leader for Immunology Therapeutic Area, Janssen Human Microbiome Institute, Janssen Immunoscience & Janssen Prevention Centre
Dr Anthony Rowe is currently a Business Technology Leader at Janssen Research and Development where he is responsible for defining the digital strategy for the Janssen's Immunology Therapeutic Area, ImmunoScience Centre of Excellence, Disease Prevention Centre and Human Microbiome Institute. He is passionate about Digital Health and Precision Medicine and its use in developing patient centric healthcare solutions. Prior to joining Janssen he was a Director of Product Management & Founding Member of InforSense Ltd an innovative big data analytics company that provided Pharmaceutical, Financial Services and Telecommunication customers access to machine learning and high performance computing technology. During his tenure at Inforsense he had roles leading Engineering, Marketing, Technical Sales as well as Product Management and was involved in both fund raising, growing the company from 7 to 150 people and a successful exit of the company. Dr Rowe holds a PhD in Computer Science and an MSc in Artificial Intelligence from Imperial College London and a BEng in Computer Systems Engineering from the University of Warwick.
Pek Lum, Ph.D. | CEO & Founder, CapellaBio
Pek is the founder and CEO of CapellaBio. CapellaBio is a VC funded computational pharmaceutical company based in Palo Alto, CA. CapellaBio applies data analysis techniques and algorithms to every step of the drug discovery and development pipeline to identify compounds, markers and new targets for specific patient populations. At the heart of CapellaBio's analysis pipeline is the SMarTR engine, a proprietary, highly automated and scalable computational platform that characterizes disease heterogeneity and identifies compounds that will be effective for specific patient sub-populations. Pek is a biologist who has been in data, software and pharmaceuticals for the past 17 years. Pek's initial start in genomics was with Rosetta Inpharmatics, a genomics and microarray company that went public and was subsequently bought by Merck & Co. Pek spent another 8 years at Merck applying data, algorithms and biology to Merck's drug discovery pipeline. Most recently, she was the VP of Product and Chief Data Scientist for Ayasdi, an enterprise software company. Pek received her B.S. and M.S. from Hokkaido University, Japan and her Ph.D. from the University of Washington, Seattle. Her work has been widely published in scientific and medical journals, and her research has contributed to discoveries in drug development and the understanding of complex diseases.
Connect with Pek:
Save This Event
When & Where
JLABS Bay Area
JLABS, part of Johnson & Johnson Innovation, LLC, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas. JLABS is an open innovation model, and the agreement for space does not grant JLABS or Johnson & Johnson Innovation any stake or rights in the companies, nor will the companies have a guaranteed future affiliation with JLABS. The flagship facility is located in San Diego at Janssen's West Coast Research Center, and JLABS has now two established locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility - one in Boston through a collaboration with Lab Central, one in Houston through a collaboration with TMC, and one in Toronto through a collaboration with MaRS. For more information please visit jlabs.jnjinnovation.com.